Business Wire

NetBet: Auto manufacturers to face fines of €11.4 billion for exceeding EU carbon targets

Share

None of the top ten car manufacturers are close to meeting EU carbon targets and could face annual fines of €11.4 billion each as a result, new research shows.

The Auto Emissions Report found that Daimler AG is the carmaker that’s furthest away from achieving the 2021 EU target of 95CO2g/km average fleet emissions, while Toyota Industries is the closest to lowering its carbon footprint - but still faces significant fines.

Automakers need to substantially reduce their annual carbon footprint in order to meet EU emissions standards, or else face fines of €95 per CO2g/km that exceeds the target, multiplied by unit sales. Based on the fleet emissions and unit sales of top manufacturers over the last year, this equates to a staggering €11,462,337,802 on average in penalties each.

As well as paying fines for exceeding EU targets, auto manufacturers would also have to offset the emissions of their annual sales. In 2019, top ten car makers would have had to pay a collective €424 billion - or an average of 39.5% of their annual revenue each.

Manufacturers and distance from EU target

Manufacturer

Distance from EU target - CO2g/km

Manufacturer

Distance from EU target - CO2g/km

Daimler AG

42

Ford Motor Company

28.7

Mazda Motor Corporation

40.2

Hyundai Motor Group

26.9

BMW

32

Groupe PSA

19.1

Fiat Chrysler Automobiles

29.4

Renault

18.2

Volkswagen Group

29

Toyota Industries

6.3

An analysis of the best-selling models of each brand reveals that Group PSA produced the most polluting cars on average last year, which would cost €1.3 billion to offset. Based on EU sales, the most polluting model sold last year was the Renault Clio.

Dissecting the running costs of manufacturers’ flagship models shows that the Mercedes-AMG GT was the most polluting model on the market last year, while the Peugeot 508 was the most environmentally friendly. Despite this, the 508’s carbon footprint is still equivalent to consuming 12,208 litres of gas, or 10,659 litres of diesel.

The transport industry is one of the largest contributors to the global carbon footprint, accounting for an estimated 24% of the world’s greenhouse gas emissions last year. Although many manufacturers are electrifying their fleet to reduce emissions, the car making sector is facing more pressure than ever to tackle their contribution to climate change.

To see the results of the Auto Emissions Report, visit: https://www.netbet.co.uk/auto-emission-report/

Data gathered from a range of sources, including auto manufacturers’ annual reports, EUROPA, transportenvironment.org and Carbon Engineering. Tonnes are metric.

Contact information

For more information or a list of sources:
Please contact: Claudia Georgevici
E-mail: pr@netbet.com
Tel: +44(0)20 7921 3810

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen

A Continuous Journey of Digital Transformation, Alibaba Cloud and Its Global Customers at Apsara 202018.9.2020 05:00:00 CESTPress release

As the digital technology and intelligence backbone of Alibaba Group, Alibaba Cloud is experiencing continuous growth alongside its customers across different parts of the world. Over the years, it has made relentless efforts to serve clients from every industry, helping them accelerate their business development and navigate the challenges of these volatile times. Cloud computing and AI technology have been shown to be the cornerstone for businesses seeking to be fully equipped in the digital era, especially following the global outbreak of COVID-19. At the 12th Apsara Conference: Leap into the Future of Digital Intelligence, customers from various sectors, including aviation, leisure and hospitality, education, and e-commerce and retail, share their growth and success stories achieved together with Alibaba Cloud. “It is our utmost pleasure to see our customers experience a seamless transition into more digitalised operations,” said Selina Yuan, President for International Business, A

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer18.9.2020 00:05:00 CESTPress release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), and the first reported data from the pivotal Phase 2 trial of its investigational PARP inhibitor pamiparib in advanced ovarian cancer (OC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which takes place on September 19-21. “We are pleased to share the promising RATIONALE 304 results, which were used to support our recently accepted supplemental new drug application in first-line non-squamous NSCLC in China,” commented Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. “BeiGene is evaluating tislelizuma

Sensorion Launches a Capital Increase by Means of an Accelerated Bookbuild Offering17.9.2020 19:33:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, intends to issue new ordinary shares of a nominal value of €0.10 (the “New Shares”) for a total capital increase of approximately €30 million (US$35 million), by means of an accelerated bookbuild offering to the benefit of categories of persons (the “ReservedOffering”). The New Shares will be issued through a share capital increase without shareholders’ preferential subscription rights pursuant to the 12th resolution of the extraordinary general meeting of shareholders of the Company held on May 20, 2020 and in accordance with Article